Catalent Pharma Solutions

Article

Sponsored Content

Catalent has a comprehensive range of fill/finish services within its global network of facilities, including sterile services and advanced aseptic technologies.
The company’s 265,000 sq ft Brussels facility has the capacity to produce more than 200 million pre-filled syringe units annually, and Catalent’s ADVASEPT® blow-fill-seal technology is designed for the safe and efficient glass-free delivery of injectable medications.

Catalent Pharma Solutions  
14 Schoolhouse Road, Somerset, NJ 08873  
tel. +1 888 SOLUTION 

Recent Videos
From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities
From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities
A CDMO’s Role in API Quality
A CDMO’s Role in API Quality
CPHI Americas 2025: The Evolving Role of the CDMO
CPHI Americas 2025: The Evolving Role of the CDMO
Inside Experic: Revolutionizing CDMO & Clinical Packaging Services
Inside Experic: Revolutionizing CDMO & Clinical Packaging Services
Drug Digest: Patient Preference Drives Solid Dosage Trends
Drug Digest: Patient Preference Drives Solid Dosage Trends
Ask the Expert: Quality Control Units
Ask the Expert: Quality Control Units
Behind the Headlines, Episode 17
Behind the Headlines, Episode 17: Bespoke CRISPR Therapy, Executive Order Fallout, and More
Industry Outlook 2025: European Political Impacts on the Supply Chain
Industry Outlook 2025: European Political Impacts on the Supply Chain
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
Related Content
Teva Pharmaceuticals manufacturing site. Locally, Teva produces oral solid medicines and packaging. | Image Credit: © jetcityimage - stock.adobe.com

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

Patrick Lavery
May 30th 2025
Article

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
May 30th 2025
Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

A lab technician in protective gear operates a tablet displaying a green checkmark in a high-tech pharmaceutical laboratory. | Image Credit: © greenbutterfly - stock.adobe.com

Companies Reveal Their Next Moves in Manufacturing

Patrick Lavery
May 29th 2025
Article

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Site Logo

End-to-end regulatory CDMO solutions: development, manufacturing, and approval (May 2025)

Lonza
May 29th 2025
Article

Site Logo

Exploring the need for dose-flexible manufacturing

Lonza
May 29th 2025
Article